医学
双特异性抗体
抗体
皮肤病科
免疫学
癌症研究
药理学
单克隆抗体
作者
Marion Lery,Aurore Perrot,Ariadna Ortiz‐Brugués,Émmanuelle Vigarios,Diana Anghel,Pierre Bories,V. Sibaud
标识
DOI:10.1016/j.jaad.2023.08.094
摘要
To the Editor: Talquetamab is a first-in-class monoclonal antibody targeting both the G protein-coupled receptor family C class 5 member D (GPRC5D) and T-cell receptor CD3. Talquetamab redirects T cells to mediate killing of GPRC5D-expressing myeloma cells.1 The use of this bispecific T-cell engager has been associated with promising results in phase I and II clinical trials for relapsed or refractory multiple myeloma.2
科研通智能强力驱动
Strongly Powered by AbleSci AI